ATE463241T1 - Neuartige zusammensetzung - Google Patents

Neuartige zusammensetzung

Info

Publication number
ATE463241T1
ATE463241T1 AT08166881T AT08166881T ATE463241T1 AT E463241 T1 ATE463241 T1 AT E463241T1 AT 08166881 T AT08166881 T AT 08166881T AT 08166881 T AT08166881 T AT 08166881T AT E463241 T1 ATE463241 T1 AT E463241T1
Authority
AT
Austria
Prior art keywords
new composition
formoterol
budesonide
formulation
treatment
Prior art date
Application number
AT08166881T
Other languages
English (en)
Inventor
Nayna Govind
Maria Marlow
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20286853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE463241(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE463241T1 publication Critical patent/ATE463241T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Networks Using Active Elements (AREA)
AT08166881T 2002-02-01 2003-01-29 Neuartige zusammensetzung ATE463241T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0200312A SE0200312D0 (sv) 2002-02-01 2002-02-01 Novel composition

Publications (1)

Publication Number Publication Date
ATE463241T1 true ATE463241T1 (de) 2010-04-15

Family

ID=20286853

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03703575T ATE423552T1 (de) 2002-02-01 2003-01-29 Zusammensetzung zur inhalation
AT08166881T ATE463241T1 (de) 2002-02-01 2003-01-29 Neuartige zusammensetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03703575T ATE423552T1 (de) 2002-02-01 2003-01-29 Zusammensetzung zur inhalation

Country Status (28)

Country Link
US (8) US7759328B2 (de)
EP (2) EP2036549B1 (de)
JP (2) JP2005521663A (de)
KR (2) KR20090125857A (de)
CN (1) CN1287774C (de)
AT (2) ATE423552T1 (de)
AU (1) AU2003206289B2 (de)
BR (1) BR0307193A (de)
CA (1) CA2474479C (de)
CO (1) CO5611098A2 (de)
CY (2) CY1109030T1 (de)
DE (2) DE60326320D1 (de)
DK (2) DK1474117T3 (de)
ES (2) ES2321180T3 (de)
HK (1) HK1126684A1 (de)
IL (1) IL163160A (de)
IS (2) IS7360A (de)
MX (1) MXPA04007295A (de)
NO (1) NO337006B1 (de)
NZ (1) NZ534452A (de)
PL (1) PL211836B1 (de)
PT (2) PT2036549E (de)
RU (1) RU2301673C2 (de)
SE (1) SE0200312D0 (de)
SI (2) SI2036549T1 (de)
UA (1) UA79445C2 (de)
WO (1) WO2003063842A1 (de)
ZA (1) ZA200406086B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
DK1845994T3 (da) * 2005-02-11 2009-05-04 Argenta Discovery Ltd Kombination af methylxanthinforbindelser og steroider til at behandle kroniske luftvejssygdomme
US9084799B2 (en) 2005-02-11 2015-07-21 Pulmagen Therapeutics (Synergy) Limited Inhaled combination therapy
DE102006053374A1 (de) * 2006-02-09 2007-08-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung für Aerosole mit zwei oder mehr Wirkstoffen und mindestens einer oberflächenaktiven Substanz
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
EP2077132A1 (de) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Abgabevorrichtung, Aufbewahrungsvorrichtung und Verfahren zur Abgabe einer Formulierung
US20130160761A1 (en) * 2008-11-04 2013-06-27 Cipla Limited Pharmaceutical Aerosol Composition
NZ574666A (en) * 2009-02-05 2009-04-30 Nexus6 Ltd A medicament inhaler holder that uses optical means to count and display the number of doses used
WO2010112358A2 (de) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh Verfahren zur beschichtung einer oberfläche eines bauteils
JP5763053B2 (ja) 2009-05-18 2015-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アダプタ、吸入器具及びアトマイザ
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EA026241B1 (ru) 2009-11-25 2017-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Распылитель
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EP3871676A1 (de) * 2010-07-16 2021-09-01 Cipla Limited Pharmazeutische zusammensetzungen enthaltend r(+) budesonid und arformoterol
CN103052378A (zh) * 2010-08-03 2013-04-17 奇斯药制品公司 包含磷酸二酯酶抑制剂的药物制剂
EP2618818A4 (de) * 2010-09-22 2014-10-29 Map Pharmaceuticals Inc Corticosteroidpartikel und herstellungsverfahren dafür
US20120204871A1 (en) 2011-02-10 2012-08-16 Julio Cesar Vega Stable, non-corrosive formulations for pressurized metered dose inhalers
TWI399202B (zh) * 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
US9241904B1 (en) 2011-08-19 2016-01-26 Intech Biopharm Ltd. Method for preparing metered dose sprayed inhaler for treating respiratory disease
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
US9744313B2 (en) 2013-08-09 2017-08-29 Boehringer Ingelheim International Gmbh Nebulizer
EP2835146B1 (de) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Zerstäuber
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
EP3139984B1 (de) 2014-05-07 2021-04-28 Boehringer Ingelheim International GmbH Zerstäuber
DK3139979T3 (da) 2014-05-07 2023-10-09 Boehringer Ingelheim Int Enhed, forstøver og fremgangsmåde
NZ724449A (en) 2014-05-07 2022-01-28 Boehringer Ingelheim Int Nebulizer and container
US20170189329A1 (en) 2014-07-29 2017-07-06 3M Innovative Properties Company Method of preparing a pharmaceutical composition
BR122020022602B1 (pt) 2015-12-04 2024-03-05 Mexichem Fluor S.A. De C.V. Composição farmacêutica
CN106581010B (zh) * 2016-12-28 2019-03-05 四川普锐特医药科技有限责任公司 一种气溶胶制剂及定量吸入气雾剂
AU2018318123B2 (en) 2017-08-15 2024-07-25 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
AU2019287541A1 (en) 2018-06-14 2021-01-21 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
JP7402631B2 (ja) 2018-08-27 2023-12-21 帝人株式会社 極細炭素繊維混合物、その製造方法、及び炭素系導電助剤
CN109464429B (zh) * 2018-12-13 2021-04-27 上海方予健康医药科技有限公司 一种吸入压力定量气雾剂药物组合物及其制备方法
CN112137957B (zh) 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL103238A (en) 1991-09-25 1995-07-31 Fisons Plc Pressed aerosol preparations
US6123924A (en) * 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
CZ288032B6 (cs) 1991-12-18 2001-04-11 Aktiebolaget Astra Farmaceutický prostředek pro podání inhalací
DE19536902A1 (de) * 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
ES2178015T3 (es) * 1996-11-11 2002-12-16 Sepracor Inc Procedimiento de preparacion de isomeros de formoterol opticamente puros.
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
NZ509328A (en) 1998-07-24 2002-11-26 Jago Res A Medicinal aerosol formulations
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009584D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0016876D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition

Also Published As

Publication number Publication date
JP2010132695A (ja) 2010-06-17
CN1625392A (zh) 2005-06-08
CY1110081T1 (el) 2015-01-14
US8143239B2 (en) 2012-03-27
ES2342509T3 (es) 2010-07-07
HK1126684A1 (en) 2009-09-11
PT2036549E (pt) 2010-06-22
IS9028A (is) 2013-04-16
NO20043458L (no) 2004-08-19
RU2004122921A (ru) 2005-06-10
KR20040081757A (ko) 2004-09-22
CA2474479C (en) 2011-04-05
US20140286878A1 (en) 2014-09-25
MXPA04007295A (es) 2004-10-29
PL211836B1 (pl) 2012-06-29
RU2301673C2 (ru) 2007-06-27
US10166247B2 (en) 2019-01-01
SI1474117T1 (sl) 2009-06-30
US7759328B2 (en) 2010-07-20
UA79445C2 (en) 2007-06-25
SI2036549T1 (sl) 2010-07-30
CN1287774C (zh) 2006-12-06
EP2036549B1 (de) 2010-04-07
US20210069215A1 (en) 2021-03-11
US11311558B2 (en) 2022-04-26
ZA200406086B (en) 2006-01-25
EP1474117A1 (de) 2004-11-10
DE60332067D1 (de) 2010-05-20
US20100275913A1 (en) 2010-11-04
US20120216802A1 (en) 2012-08-30
DK1474117T3 (da) 2009-05-25
NZ534452A (en) 2006-01-27
EP1474117B1 (de) 2009-02-25
WO2003063842A9 (en) 2004-04-22
US20050089478A1 (en) 2005-04-28
CO5611098A2 (es) 2006-02-28
KR100947168B1 (ko) 2010-03-12
KR20090125857A (ko) 2009-12-07
ES2321180T3 (es) 2009-06-03
WO2003063842A1 (en) 2003-08-07
IS2960B (is) 2017-02-15
US20160022703A1 (en) 2016-01-28
PL372118A1 (en) 2005-07-11
CY1109030T1 (el) 2014-07-02
DE60326320D1 (de) 2009-04-09
BR0307193A (pt) 2004-11-03
JP5259636B2 (ja) 2013-08-07
US8575137B2 (en) 2013-11-05
NO337006B1 (no) 2015-12-21
ATE423552T1 (de) 2009-03-15
AU2003206289B2 (en) 2007-09-06
JP2005521663A (ja) 2005-07-21
US20190216828A1 (en) 2019-07-18
DK2036549T3 (da) 2010-07-12
SE0200312D0 (sv) 2002-02-01
EP2036549A1 (de) 2009-03-18
CA2474479A1 (en) 2003-08-07
PT1474117E (pt) 2009-04-24
US20170368078A1 (en) 2017-12-28
IS7360A (is) 2004-07-21
IL163160A (en) 2013-12-31

Similar Documents

Publication Publication Date Title
CY1110081T1 (el) Νεα συνθεση
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
CY2014019I2 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
NO20033594D0 (no) Fenetanolamin-derivater for behandling av luftveissykdommer
DE602004029367D1 (de) Therapeutische und/oder präventive zusammsentzung für periodontale erkrankungen
CY2018006I2 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
SG148194A1 (en) Compositions for the treatment of affections of the oral cavity and upper respiratory tract
HRP20050579B1 (hr) Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol
EA200500328A1 (ru) Композиция и лекарственное средство для лечения респираторных заболеваний, аллергических заболеваний, астмы и/или хронических обструктивных заболеваний легких и способ получения лекарственного средства
DK1670482T4 (da) Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
ATE501719T1 (de) Methoden und zusammensetzungen zur beruhigung von mund- und nasenschleimhäuten
EE200400074A (et) Koostised ning nende kasutamine proliferatiivsetehaiguste raviks
DE60212349D1 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines pharmazeutischen mittels zur prävention und behandlung von sexuellen störungen
EP1677745A4 (de) Nitron-verbindungs-prodrugs und pharmazeutische zusammensetzung daraus zur behandlung von menschlichen erkrankungen
ITMI20021455A0 (it) Formulazioni fosfolipidiche di lexitropsine loro preparazione ed impiego terapeutico
IL165653A (en) Compounds, compositions comprising them and use thereof for the manufacture of medicaments for the treatment of inflammatory diseases, disorders and conditions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2036549

Country of ref document: EP